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Abstract
 
Chemokines are a family of small proteins that interact with seven-transmembrane domain re-
ceptors and modulate the migration of immune cells into sites of inflammation and infection.
The murine gammaherpesvirus 68 
 
M3
 
 gene encodes a secreted 44-kD protein with no se-
quence similarity to known chemokine receptors. We show that M3 binds a broad range of
chemokines, including CC, CXC, C, and CX
 
3
 
C chemokines, but does not bind human B
cell–specific nor mouse neutrophil–specific CXC chemokines. This herpesvirus chemokine
binding protein (hvCKBP) blocks the interaction of chemokines with high-affinity cellular re-
ceptors and inhibits chemokine-induced elevation of intracellular calcium levels. hvCKBP is
the first soluble chemokine receptor identified in herpesviruses; it represents a novel protein
structure with the ability to bind all subfamilies of chemokines in solution and has potential
therapeutic applications.
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Introduction
 
The migration of leukocytes from blood vessels to sites of
infection and inflammation is an important phenomenon in
host defense. Chemokines are chemotactic cytokines that
interact with G protein–coupled chemokine receptors
(CKRs) and play a key role in leukocyte recruitment; they
have also been implicated in hematopoiesis, angiogenesis,
and development (1, 2). Chemokines are divided into four
structural subfamilies based on the number and arrange-
ment of conserved cysteines: CC chemokines such as
RANTES (regulated upon activation, normal T cell ex-
pressed and secreted), macrophage inflammatory protein
(MIP)-1
 
a
 
, and monocyte chemoattractant protein (MCP)-1;
CXC chemokines such as IL-8 and growth-related onco-
gene (GRO)-
 
a
 
; the C chemokine lymphotactin; and the
CX
 
3
 
C chemokine fractalkine. Chemokines form a chemi-
cal gradient via electrostatic interactions with negatively
charged glycosaminoglycans (GAGs). The binding sites of
chemokines for GAGs and specific CKRs are distinct.
Chemokines are tightly regulated to prevent excessive
inflammation that can cause disease and represent targets
for therapeutic intervention. The production of soluble ver-
sions of cytokine receptors represents a strategy to block cy-
tokine activity (3). However, the seven-transmembrane do-
main structure of CKRs makes the construction of soluble,
inhibitory CKRs difficult, and thus antagonists based on
mutated chemokines, blocking peptides, or antibodies are
under evaluation as chemokine inhibitors (1, 2).
It has been established that molecular mimicry of cyto-
kines and cytokine receptors is a strategy adopted by large
DNA viruses to modulate the host immune response (4–7).
Poxviruses encode a unique set of secreted proteins that
bind cytokines such as TNF, IL-1
 
b
 
, IFN-
 
a
 
/
 
b
 
, IFN-
 
g
 
, and
chemokines with high affinity and block their activity by
preventing interaction with cellular receptors. Herpesvi-
ruses encode a number of cytokine homologues, including
IL-6, IL-10, and IL-17 (4), and proteins with sequence
similarity to chemokines and seven-transmembrane domain
CKRs, which modulate or utilize the chemokine network
for the benefit of the virus (7).
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Members of the gammaherpesvirus subfamily are wide-
spread in nature and are characterized by their ability to es-
tablish latency in lymphocytes and by an association with
lymphoproliferative disorders and a variety of tumors. Mu-
rine gammaherpesvirus (MHV)-68 is a natural pathogen of
murid rodents (8) genetically related to the primate gam-
maherpesviruses herpesvirus saimiri, human herpesvirus
(HHV)-8 (also known as Kaposi’s sarcoma–associated her-
pesvirus), and EBV (9–11). Interest in MHV-68 stems from
its ability to establish both acute and persistent infection
within laboratory mice, therefore offering a unique oppor-
tunity to investigate immunological and virological aspects
of gammaherpesvirus pathogenesis (12). During primary
infection of mice, acute phase virus replication is detected
in multiple organs, with latency being largely restricted to
B lymphocytes and macrophages (13–16).
Previous in situ hybridization studies have shown that
the unique MHV-68–encoded open reading frame (ORF)
 
M3
 
 is transcribed during acute infection and at early stages
of latency establishment in the spleen (17). However, the
precise function of this ORF is unclear. 
 
M3
 
 encodes a 44-kD
secreted protein translated from an abundant 1.4-kb early–late
lytic transcript, and it has been proposed that this protein may
interact with host cellular receptors or cytokines (18).
Here we report that the MHV-68–encoded M3 protein
binds chemokines from all four known subfamilies and
demonstrate that the inhibitory mechanism of the herpesvi-
rus chemokine binding protein (hvCKBP) is to block the
interaction of chemokines with cellular receptors. This rep-
resents the first protein identified in herpesviruses that is se-
creted from infected cells and sequesters chemokines.
 
Materials and Methods
 
Reagents.
 
Radioiodinated recombinant human IL-8, RANTES,
MIP-1
 
a
 
, and fractalkine (2,000 Ci/mmol) were obtained from
Amersham. Recombinant human RANTES and IL-18 and mu-
rine B cell–attracting chemokine (BCA)-1 (B lymphocyte chemo-
attractant [BLC]-1) were obtained from R & D Systems, Inc.
Recombinant human MIP-1
 
a
 
, MCP-1, MCP-4, secondary lym-
phoid tissue chemokine (SLC), IL-8, GRO-
 
a
 
, IFN-
 
g
 
–inducible
protein (IP)-10, granulocyte chemotactic protein (GCP)-2, BCA-1,
stromal cell–derived factor (SDF)-1
 
a
 
, lymphotactin, fractalkine,
and murine RANTES, MIP-1
 
a
 
, KC, MIP-2, and LPS-induced
CXC chemokine (LIX) were obtained from PeproTech, Inc.
Recombinant human and murine IL-1
 
b
 
, IFN-
 
g
 
, and TNF-
 
a
 
were obtained from PeproTech, Inc.
 
Growth of MHV-68 and Generation of Recombinant Viruses.
 
MHV-68 was grown and assayed in baby hamster kidney (BHK)-
21 cells and purified from cell supernatants by Ficoll gradient
centrifugation (19). Recombinant viruses were generated by
cotransfection of the relevant plasmid with MHV-68 virion
DNA into BHK-21 cells (19). For the generation of a recombi-
nant MHV-68 with a disrupted 
 
M3
 
 gene, two primers were used
(5
 
9
 
-GGACTCTTGAGGAGCTCGAG-3
 
9 
 
and 5
 
9
 
-TAGGTGGCT-
GCTGAGTGATT-3
 
9
 
) to PCR amplify a 2,602-bp fragment
(genomic coordinates 5,347–7,929) (10) with Taq polymerase
(Perkin-Elmer Corp.) using MHV-68 genomic DNA as tem-
plate. The PCR fragment was cloned into pCR2.1 (Invitrogen
Corp.) to yield pM3. A 4.1-kbp HindIII cassette containing the
 
LacZ gene driven by the human CMV immediate early promoter
derived from pMV10 (20) was inserted at the HincII site (coordi-
nate 7,156) in an orientation opposite to the direction of 
 
M3
 
transcription to yield pM3MV10. The virus mutant with a dis-
rupted 
 
M3
 
 ORF was named MHV-M3LacZ. For the generation
of an M3 revertant, named MHV-M3R, linearized pM3 was
cotransfected with M3 mutant virus DNA. Recombinant viruses
were identified by X-Gal staining and plaque purified three
times, and their genetic structures were confirmed by Southern
blot hybridization.
 
Growth and Construction of Recombinant Baculoviruses.
 
The MHV-
68 
 
M3
 
 ORF was amplified from infected cell DNA by PCR
using oligonucleotides 5
 
9
 
-CGCGAATTCATGGCCTTCCTAT-
CCACATCG-3
 
9
 
, inserting an EcoRI site, and 5
 
9
 
-GGTGCG-
GCCGCATGATCCCCAAAATACTCCAGC-3
 
9
 
, which inserts
a NotI site. The 1,238-bp product was cloned into EcoRI/NotI-
digested pBAC-1 (Novagen Corp.), creating pBACM3. The
nucleotide sequence of the cloned ORF was confirmed by se-
quencing before the recombinant baculovirus, named AcM3, was
constructed as described (21). Recombinant M3 protein contain-
ing a COOH-terminal 6-histidine tag was produced in 
 
Spodoptera
frugiperda
 
 (Sf)21 insect cells infected with AcM3. The recombi-
nant baculovirus AcB15R has been described (22).
 
Binding Assays.
 
Supernatants from MHV-68–infected BHK-
21 cells or baculovirus-infected Sf21 cells, infected at high multi-
plicity of infection, were harvested 2 or 3 d after infection, re-
spectively, and prepared as described (22). Infectious virus present
in supernatants was inactivated with 4,5
 
9
 
,8-trimethylpsoralen and
exposure to UV light (21). Binding medium was RPMI 1640
containing 20 mM Hepes, pH 7.4, and 0.1% BSA. Cross-linking
experiments with bis(sulfosuccinimidyl) suberate (BS
 
3
 
; 5 mM;
Pierce Chemical Co.) to 
 
125
 
I-labeled chemokines (0.4 nM) were
performed in 25 
 
m
 
l as described (21). The amount of medium
used was equivalent to 5 
 
3 
 
10
 
2
 
 cells. Samples were analyzed by
12% acrylamide SDS-PAGE. In the competition assays with
U937 cells, supernatants were preincubated with 100 pM 
 
125
 
I-labeled
chemokine in 100 
 
m
 
l for 1 h at 4
 
8
 
C. Subsequently, 2.5 
 
3 
 
10
 
6
 
U937 cells were added in 50 
 
m
 
l and incubated for 2 h at 4
 
8
 
C.
Bound 
 
125
 
I-labeled chemokine was determined by phthalate oil
centrifugation (21).
 
Measurement of Calcium Mobilization.
 
PBMCs were separated
from human whole blood by centrifugation over Lymphoprep™
reagent (Nycomed) and maintained in RPMI 1640 supplemented
with 20% FCS. Cells were incubated at a density of 2 
 
3
 
 10
 
6
 
cells/ml in RPMI 1640, 1% FCS, and 5 
 
m
 
M Indo-1 for 1 h be-
fore being washed twice in HBSS and resuspended at 10
 
5
 
 cells/ml
in HBSS/0.2% FCS. Calcium influx was monitored after the ad-
dition of 20 nM RANTES, preincubated for 2 h at room tem-
perature with baculovirus-expressed proteins, by flow cytometry
at excitation wavelengths of 480 and 400 nm using a Becton
Dickinson FACS VantageSE™ cytometer.
 
Results
 
MHV-68 Encodes a Soluble CKBP with Broad Specificity.
 
To investigate the expression of soluble CKBPs encoded
by MHV-68, binding assays with human 
 
125
 
I-labeled IL-8
(CXC chemokine), 
 
125
 
I-labeled RANTES, and 
 
125
 
I-labeled
MIP-1
 
a
 
 (CC chemokines) and the radioiodinated soluble
chemokine domain of fractalkine (CX
 
3
 
C chemokine) were
carried out with MHV-68–infected cell supernatants, fol-
lowed by chemical cross-linking with BS
 
3
 
. Complexes of 
575
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chemokines with a soluble protein were detected with all
three subfamilies of chemokines tested but not with the
control supernatant from mock-infected cultures (Fig. 1).
The size of the complex was 
 
z
 
45 kD, suggesting a viral
protein of 38 kD after subtraction of the 8-kD mass of the
monomeric 
 
125
 
I-labeled chemokines. The higher molecular
size complex observed was probably the result of protein
aggregation and was not observed when samples were not
boiled before the electrophoretic analysis (data not shown).
Analysis of the MHV-68 genomic sequence failed to
identify a secreted protein with sequence similarity to
CKRs (10). However, a possible candidate was the 44-kD
secreted protein encoded by ORF 
 
M3
 
 (18). On this basis,
the 
 
M3
 
 ORF was inactivated by insertion of a LacZ ex-
pression cassette and the mutant virus designated MHV-
M3LacZ (Fig. 2 B). A revertant virus named MHV-M3R
in which the 
 
M3
 
 ORF was reinserted into the virus ge-
nome was also constructed to control for possible muta-
tions elsewhere in the viral genome. Fig. 2 A shows that
supernatants from wild-type MHV-68 and revertant virus
infections formed a complex with 
 
125
 
I-labeled RANTES
after cross-linking, whereas supernatants from M3 mutant
and mock infections did not produce a complex. To fur-
ther demonstrate that the M3 protein binds chemokines, a
recombinant baculovirus named AcM3 was constructed
that expressed the 
 
M3
 
 ORF. Medium from insect cells in-
fected with AcM3 formed a complex with 
 
125
 
I-labeled IL-8
of size similar to that observed with MHV-68–infected cell
supernatants (Fig. 2 A). This complex was not found with
the control recombinant baculovirus AcB15R expressing
the vaccinia virus soluble IL-1
 
b
 
R.
 
Chemokine Binding Specificity of hvCKBP.
 
To determine
the binding specificity of M3, cross-linking experiments
were carried out with radiolabeled CC and CXC chemo-
kines in the presence of various amounts of unlabeled chemo-
kine competitors. Fig. 3 shows that the binding to 
 
125
 
I-labeled
IL-8 and 
 
125
 
I-labeled MIP-1
 
a
 
 was inhibited by all of the
unlabeled CC chemokines tested. In addition, viral (v)MIP-2
encoded by HHV-8 bound to hvCKBP in a similar com-
petition experiment (data not shown). CXC chemokines
such as human GRO-
 
a
 
 and IP-10 and murine BCA-1 also
inhibited binding to both 
 
125
 
I-labeled IL-8 and 
 
125
 
I-labeled
MIP-1
 
a
 
. Other CXC chemokines, including murine KC
(murine GRO-
 
a
 
), MIP-2, and LIX and human BCA-1
and SDF-1
 
a
 
 were poor inhibitors of the binding to 
 
125
 
I-labeled
chemokines. Human lymphotactin and the soluble chemo-
kine domain of human fractalkine, the single members of
the C and CX
 
3
 
C chemokine subfamilies, respectively, also
inhibited binding to both 
 
125
 
I-labeled IL-8 and 
 
125
 
I-labeled
MIP-1
 
a
 
. The competition profiles of the chemokines tested
Figure 1. A soluble chemokine binding activity is encoded by MHV-68.
Media from BHK-21 cells uninfected (Mock) or infected with MHV-68
were incubated with 125I-labeled chemokines and treated with the cross-
linker BS3. An autoradiograph of the SDS-PAGE analysis, with molecular
masses in kD, is shown. The positions of the chemokines and ligand–
receptor complexes are indicated.
Figure 2. The M3 ORF encodes the soluble chemokine binding activ-
ity expressed by MHV-68. (A) Media from BHK-21 cells uninfected
(Mock) or infected with wild-type MHV-68, the M3 mutant MHV-
M3LacZ, or the revertant virus MHV-M3R were incubated with 125I-
labeled RANTES. Media from Sf21 cells infected with the recombinant
baculoviruses AcM3 or AcB15R were incubated with 125I-labeled IL-8.
Samples were treated with the cross-linker BS3. Autoradiographs of the
SDS-PAGE analysis, with molecular masses in kD, are shown. The posi-
tions of RANTES (R), IL-8, and ligand–receptor complexes (square
brackets) are indicated. (B) Diagram showing the site of insertion of LacZ
into the M3 gene of MHV-68 to yield a recombinant virus with the M3
gene disrupted, designated MHV-M3LacZ. The MHV-68 genome con-
tains 118,237 bp of unique sequence flanked by variable copies of a
1,213-bp terminal repeat (10). The leftmost end of the virus genome is
expanded, depicting the first ORFs, M1 to M4, interspersed by the eight
viral tRNA–like molecules (25). The HincII site at position 7,157 indi-
cates the site of insertion of MV10 containing the LacZ gene. 
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suggested different affinities of hvCKBP for various chemo-
kines. The interaction between hvCKBP and 
 
125
 
I-labeled
chemokines was not inhibited by a 500-fold excess of a va-
riety of cytokines, including human and mouse IL-1
 
b
 
, IL-
18, IFN-
 
g
 
, and TNF-
 
a
 
, indicating binding specificity for
chemokines (data not shown). The recombinant M3 pro-
tein produced in the baculovirus system showed the same
chemokine binding specificity in similar competition ex-
periments with 
 
125
 
I-labeled MIP-1
 
a
 
 and 
 
125
 
I-labeled IL-8 in
the presence of excess unlabeled chemokines (data not
shown).
To demonstrate that hvCKBP does not bind to the
chemokine GAG binding domain, radiolabeled ligands were
preincubated with different doses of heparin and heparan
sulfate before the addition of MHV-68 supernatants. Prein-
cubation with heparin or heparan sulfate, representing a 3 
 
3
 
10
 
6
 
 molar excess over the chemokines in the case of hep-
arin, had no effect on the binding of 
 
125
 
I-labeled IL-8 or
 
125
 
I-labeled MIP-1
 
a
 
 to hvCKBP (Fig. 3).
 
hvCKBP Blocks the Binding of Chemokines to Cell Surface
Receptors.
 
Specific binding of 
 
125
 
I-labeled MIP-1
 
a
 
 and
125I-labeled IL-8 to U937 cells was inhibited in a dose-
dependent manner by supernatants from cultures infected
with wild-type MHV-68 or recombinant baculovirus AcM3
but not by the virus mutant MHV-M3LacZ or the recom-
binant baculovirus AcB15R expressing the vaccinia virus
soluble IL-1bR (Fig. 4). The partial inhibitory effect with
high doses of MHV-M3LacZ supernatants was also ob-
served with mock-infected BHK-21 supernatants (data not
shown). Inhibition of chemokine binding to cells was
achieved by very low doses of supernatant containing the
natural or recombinant M3 protein and was more efficient
for IL-8 (0.1 ml, equivalent to supernatant from 250 infected
cells) than MIP-1a (1 ml, equivalent to supernatant from
3,000 infected cells).
hvCKBP Blocks the Biological Activity of Chemokines.
Recombinant hvCKBP specifically inhibited, in a dose-
dependent manner, the transient increase in intracellular
calcium induced by RANTES in human PBMCs (Fig. 5).
Discussion
This paper describes the identification and characterization
of a novel soluble CKBP encoded by the MHV-68 M3
ORF. The secreted M3 protein shows no amino acid se-
quence similarity to seven-transmembrane domain CKRs,
which are hydrophobic molecules that cannot be engineered
as soluble chemokine inhibitors (1, 2). A number of her-
pesviruses encode homologues of membrane-bound cellular
CKRs (7), but hvCKBP is the first example of a soluble in-
hibitor encoded by a herpesvirus that sequesters chemokines.
A soluble colony-stimulating factor 1 receptor encoded by
EBV is the only soluble cytokine receptor identified in the
herpesvirus family to date (23), and several soluble cytokine
receptors are expressed by poxviruses (5, 6, 24). hvCKBP may
be a unique herpesvirus molecule or may represent a viral
version of an unidentified cellular molecule.
The M3 gene product is unique to MHV-68, with no
identifiable homology to known cellular or viral proteins,
but displays significant sequence similarity to the MHV-68
ORF M1 (17, 18), which is dispensable for the establish-
ment of and reactivation from latency (19). The M1 trans-
lation product, but not the M3 protein, has amino acid se-
quence similarity to members of the poxvirus serpin family,
Figure 3. Binding specificity of hvCKBP en-
coded by MHV-68. Cross-linking of 0.4 nM hu-
man 125I-labeled MIP-1a or 125I-labeled IL-8 with
BS3 to medium from uninfected (Mock) and
MHV-68–infected cultures, in the absence (NC)
or presence of increasing doses of the indicated
unlabeled human or murine chemokines. The
concentrations of unlabeled chemokines were 10-,
100-, 500-, and 2,000-fold excess. In the cross-
linking performed in the presence of GAGs, radio-
labeled MIP-1a and IL-8 were preincubated with
heparin or heparan sulfate for 1 h at room temper-
ature before addition of supernatants. The doses of
heparin and heparan sulfate added were 1,000,
100, 10, 1, 0.1, 0.01, and 0.001 mg/ml. An auto-
radiograph of the SDS-PAGE analysis showing
the ligand–hvCKBP complexes is shown.577 Parry et al. Brief Definitive Report
although the functionally important serpin hinge region is
not conserved (10, 25). The absence of chemokine binding
activity in the M3 mutant MHV-M3LacZ suggests that M3
is the only MHV-68 CKBP. However, M1 transcription
has not been detected in BHK-21 cells (17), and thus the
M1 ORF may also encode chemokine binding activity.
We show that hvCKBP interacts with the receptor bind-
ing domain of chemokines, at a site different to the GAG
binding domain. Consistent with this observation, hvCKBP
blocks at very low doses the binding of IL-8 and MIP-1a
to high-affinity cellular CKRs and RANTES-induced sig-
nal transduction in vitro. This indicates that the affinity of
hvCKBP for these chemokines is similar to or higher than
their affinity for cellular receptors. Furthermore, it estab-
lishes the mechanism of action of hvCKBP and shows that
hvCKBP is a potent chemokine inhibitor.
hvCKBP exhibits a broad binding specificity, extending
to all subfamilies of chemokines and vMIP-2 encoded by
HHV-8. Interestingly, hvCKBP does not bind to human B
cell–specific or murine neutrophil–specific CXC chemo-
kines, which may be of relevance in viral pathogenesis. The
broad binding specificity of hvCKBP is unique amongst
known CKRs. A soluble 35-kD CKBP encoded by poxvi-
ruses that binds a broad range of CC chemokines but not
CXC or C chemokines has been described (6). The poxvi-
rus CKBP has no sequence similarity to the M3 protein
and is likely to interact with chemokines in a different way.
Future structural analysis of these viral CKBPs will establish
the molecular interaction of soluble chemokine inhibitors
with their ligands and may help to design small soluble in-
hibitors of chemokines.
Expression of a broad range and potent soluble CKBP by
MHV-68–infected cells indicates an immune modulatory
role for the M3 protein. M3 is abundantly expressed during
lytic infection in the lungs of infected mice (11), and this
may delay leukocyte influx into infected areas. Notably,
M3 transcription has also been detected in spleens of la-
tently infected mice (17, 26) and is localized to periarteri-
olar lymphoid sheets early during the establishment of la-
tency (17). The M3 protein does not bind human BCA-1
but binds the mouse homologue. Further investigations to
determine whether the binding affinity of hvCKBP for
mouse BCA-1 is sufficient to block its biological activity
will be important, as BCA-1 is required for formation of
germinal centers (27, 28), where MHV-68 latency is con-
fined within the spleen (17, 25).
The important role of chemokines and CKRs in antivi-
ral defense is emphasized by the various strategies encoded
by large DNA viruses to modulate chemokine activity.
These include the expression of secreted CKBPs that block
interaction of chemokines with cellular receptors or GAGs
(5, 6, 24), chemokine-like proteins that may block or acti-
vate specific chemokine pathways (7), and seven-transmem-
brane domain CKR homologues that may downregulate
the local concentration of chemokines or hijack chemo-
kine-induced signals (7). Some of these viral proteins, such
as the HHV-8 vMIP-2 that has angiogenic properties (29),
may also contribute directly to pathology.
Viral proteins that counteract the immune system have
been optimized during evolution and represent potential
sources of immunomodulatory proteins (4–6, 24). As
chemokines have been implicated in many disease pro-
cesses, such as rheumatoid arthritis, transplant rejection,
HIV progression, and atherosclerosis, the novel soluble
chemokine inhibitor encoded by MHV-68 has potential
therapeutic applications. The existence of a large number
of chemokines suggests redundancy, and thus the therapeu-
tic use of a broad chemokine antagonist such as hvCKBP
may be advantageous. In addition, hvCKBP may provide
the structural scaffolding needed to design soluble chemo-
kine inhibitors with a narrower specificity.
Figure 4. Natural and recombinant hvCKBP block the specific binding
of MIP-1a and IL-8 to U937 cells. Binding assay of 125I-labeled MIP-1a
and 125I-labeled IL-8 to U937 cells in the presence of supernatants from
cells infected with MHV-68 or MHV-M3LacZ or with recombinant
baculovirus AcM3 or AcB15R. The dose of supernatant corresponding to
a number of cells (cell equivalents) is indicated. The binding specificity
was determined in the presence of a 1,000-fold excess of unlabeled MIP-1a
or IL-8. Means (6SEM) from duplicate samples are expressed as the per-
centage of counts binding in the absence of competitor.
Figure 5. Recombinant hvCKBP blocks chemokine biological activity
in vitro. Elevation of intracellular calcium levels in human PBMCs by 20 nM
RANTES, preincubated with or without supernatants from cultures in-
fected with recombinant baculovirus AcM3 or AcB15R. The dose of su-
pernatant corresponding to a number of cells (cell equivalents) is indi-
cated. Cell signaling is expressed as the percentage of cells with elevated
calcium levels in the presence of RANTES alone.578 Herpesvirus Chemokine Binding Protein
The MHV-68 chemokine inhibitor reported here repre-
sents a novel virus immune evasion strategy that provides
insights into herpesvirus–host interactions and the mecha-
nisms of herpesvirus pathogenesis.
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